Back to Search Start Over

Whole breast radiotherapy in cN0 early breast cancer patients with pathological sentinel lymph nodes (pN1mic, pN1a) without axillary dissection: preliminary results of the observational LISEN trial.

Authors :
Ursini LA
Nuzzo M
Rosa C
Borgia M
Caravatta L
Di Tommaso M
Trignani M
Di Guglielmo FC
Ausili Cefaro G
Angelucci D
Muzi M
Martino G
Cianchetti E
Grossi S
Tavoletta S
Brocco D
Grassadonia A
Tinari N
Gildetti S
D'Ostilio N
Stuppia L
Porreca A
Di Nicola M
Genovesi D
Source :
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] [Strahlenther Onkol] 2022 Jul; Vol. 198 (7), pp. 612-621. Date of Electronic Publication: 2022 May 02.
Publication Year :
2022

Abstract

Purpose: Axillary management remains unclear when sentinel lymph node (SLN) results are positive in cN0 patients with breast cancer (BC). The trial ACOSOG Z0011 represented a revolution with axillary lymph node dissection (ALND) omission in SLN+ patients, despite critiques regarding non-uniformity of radiation fields. We conducted an observational study (LISEN) where whole breast radiotherapy (WBRT) was planned with tangential fields without nodal irradiation in patients eligible for the Z0011 trial.<br />Methods: Inclusion criteria were female patients with histologically proven BC, cT1-2cN0, planned conservative surgery, no neoadjuvant therapy. Patients were stratified into two groups: micrometastatic (pN1mic, group 1) and macrometastatic (pN1a, group 2) lymph nodes. Tangential field WBRT was mandatory. Clinical outcomes were analysed, measured from surgery until the first event.<br />Results: In all, 199 patients underwent conservative surgery and SLN biopsy; 133 patients meeting criteria were analysed: 41 patients (30.8%) pN1mic and 92 (69.2%) pN1a. The 5‑year disease-free survival (DFS) was 95.0% (85.9-100%) in group 1 and 93.0% (86.3-100.0%) in group 2 (p = 0.78). Overall survival (OS) was 100% (100-100%) in group 1 and 97.4% (92.4-100%) in group 2 (p = 0.74). For the whole cohort DFS and OS were 93.6% (88.2-99.4%) and 96.9% (91.5-100.0%), respectively. For groups 1 and 2, the 5‑year outcomes were 5.0% (0.0-14.4%) and 2.3% (0.0-6.1%) for local recurrence (p = 0.51), and 6.2% (0.0-17.4%) and 7.0% (0.0-13.7%) for distant metastasis (p = 0.61), respectively. In group 1, regional recurrence (RR) and local regional recurrence (LRR) were 5.0% (0.0-14.1%; p = 0.13). In group 2, RR and LRR were 0.0% (0.0-0.0%).<br />Conclusion: Our results showed good regional control in patients who met the Z0011 trial criteria. WBRT, without nodal surgery or RT, avoiding axillary morbidity, seems to be a good choice.<br /> (© 2022. The Author(s).)

Details

Language :
English
ISSN :
1439-099X
Volume :
198
Issue :
7
Database :
MEDLINE
Journal :
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
Publication Type :
Academic Journal
Accession number :
35499695
Full Text :
https://doi.org/10.1007/s00066-022-01944-z